Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers

$1.91M USD

Funder	FOOD AND DRUG ADMINISTRATION
Recipient Organization	Sloan-Kettering Inst Can Research
Country	United States
Start Date	Sep 15, 2024
End Date	Jul 31, 2028
Duration	1,415 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10974281`

Grant Description

ABSTRACT/SUMMARY Two rare types of thyroid cancer currently have extremely poor outcomes. Radioiodine-refractory (RAIR), recurrent and/or metastatic (R/M) differentiated thyroid cancer (DTC) is incurable and has a 10-year survival of ~10%. Anaplastic thyroid cancer (ATC) is a highly aggressive, dedifferentiated thyroid cancer with a median

survival of